Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.72 |
| ▸ | TKT | P29401 | 14/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1628632 | 1.00 | HSP90AA1 (0.72) | HSP90AA1TKTKDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL23630909 | 0.99 | HSP90AA1 (0.74) | HSP90AA1TKTKDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL244784 | 0.99 | HSP90AA1 (0.74) | HSP90AA1TKTKDM4ETDP1 | |
| Pyrophosphoric Acid SCHEMBL1491169 | 0.89 | HSP90AA1 (0.62) | HSP90AA1TKTTDP1 | |
| Thiamine Ion SCHEMBL30028012 | 0.87 | HSP90AA1 (0.95) | HSP90AA1TKTKDM4ETDP1 | |
| Thiamine Ion SCHEMBL7200449 | 0.87 | HSP90AA1 (0.95) | HSP90AA1TKTKDM4ETDP1 | |
| Thiamine Ion SCHEMBL258492 | 0.87 | HSP90AA1 (0.95) | HSP90AA1TKTKDM4ETDP1 | |
| Thiamine Ion SCHEMBL5317564 | 0.87 | HSP90AA1 (0.95) | HSP90AA1TKTKDM4ETDP1 | |
| Thiamine Ion SCHEMBL1251742 | 0.87 | HSP90AA1 (0.95) | HSP90AA1TKTKDM4ETDP1 | |
| Thiamine Ion SCHEMBL1644252 | 0.87 | HSP90AA1 (0.95) | HSP90AA1TKTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | claimed |
| WO-2024148139-A2 | METABOLITE-BASED PARTICLES AND COMPOSITIONS THEREOF FOR PREVENTING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-07-11 | — | — | WO | claimed |
| WO-2023089313-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | WO | claimed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | disclosed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024148139-A2 | METABOLITE-BASED PARTICLES AND COMPOSITIONS THEREOF FOR PREVENTING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023089313-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | WO | disclosed |
| US-20210085699-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | THE JACKSON LABORATORY (US) | 2021-03-25 | — | — | US | disclosed |
| EP-3755341-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | The Jackson Laboratory (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019165022-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | THE JACKSON LABORATORY (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| US-20110189689-A1 | RIBOSWITCHES | ETH ZURICH (CH) | 2011-08-04 | — | — | US | disclosed |
| EP-2294194-A2 | RIBOSWITCHES | ETH Zurich (CH) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009144588-A2 | RIBOSWITCHES | ETH ZURICH (CH) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189689-A1 | RIBOSWITCHES | TPP1, TPP2, RNGTT | HSP90AA1 1941/4885TKT 92/4885KDM4E 1980/4885 |
| US-20210085699-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | RAD51, MRE11, RAD50 | HSP90AA1 952/4885TKT 73/4885KDM4E 1912/4885 |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | POLRMT, TK2, GOT2 | HSP90AA1 2638/4885TKT 94/4885KDM4E 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.